3-(1-甲基-1,2,3,6-四氢吡啶-4-基)-5-硝基-1H-吲哚 | 106516-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(1-甲基-1,2,3,6-四氢吡啶-4-基)-5-硝基-1H-吲哚
• 英文名称: 3-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-nitro-1H-indole
• 英文别名: 5-nitro-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-1H-indole；5-nitro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole；3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-5-nitro-1H-indole；3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-5-nitro-1H-indole；3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-5-nitro-1H-indole
• CAS: 106516-27-2
• 化学式: C₁₄H₁₅N₃O₂
• 分子量: 257.292
• InChiKey: MWJUXAHARLFJAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-(1-Methyl-1,2,3,6-Tetrahydropyridin-4-Yl)-5-Nitro-
1H-Indole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 257,29 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-(1-Methyl-1,2,3,6-Tetrahydropyridin-4-Yl)-5-Nitro-1H-Indole
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-(1-Methyl-1,2,3,6-Tetrahydropyridin-4-Yl)-5-Nitro-1H-Indole
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-(1-甲基-1,2,3,6-四氢吡啶-4-基)-5-硝基-1H-吲哚 在 palladium on activated charcoal 氢气 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、137.89 kPa 条件下， 反应 20.0h， 以73%的产率得到1H-吲哚-5-胺,3-(1-甲基-4-哌啶基)-
  参考文献：
  名称：

  药物化学驱动着朝向新型和选择性5-羟色胺5-HT6受体配体的方法。

  摘要：

  基于药物化学指导的假设药效团模型，新系列的吲哚基磺酰胺已被设计和制备为选择性和高亲和性5-羟色胺5-HT（6）受体配体。此外，基于发现库的筛选方法，一系列苯并恶嗪哌啶基磺酰胺被鉴定为选择性5-HT（6）配体。本文中描述的许多化合物具有出色的亲和力，显示的pK（i）值大于8（某些甚至大于9），并且对宽范围（> 50）的其他CNS相关受体具有高选择性。首先，讨论了这些配体的结构亲和性关系。就功能而言，制备了高亲和力的拮抗剂，以及激动剂，甚至部分激动剂。化合物19c和19g代表文献中报道的最高亲和力5-HT（6）激动剂。这些有价值的工具化合物应允许详细研究5-HT（6）受体在相关的动物模型疾病中的作用，例如认知缺陷，抑郁，焦虑或肥胖。

  DOI：

  10.1021/jm049615n
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 5-硝基吲哚 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 22.0h， 生成 3-(1-甲基-1,2,3,6-四氢吡啶-4-基)-5-硝基-1H-吲哚
  参考文献：
  名称：

  通过对4-氟-N- [3-（1-（4-甲基-4-哌啶基）-1H-吲哚-5-基]苯甲酰胺衍生的5-HT1F配体进行共价二聚，设计5-HT1D受体的选择性，高亲和力配体。

  摘要：

  我们在这里证明5-HT 1配体的共价二聚是一种有效的设计策略，以调节5-HT 1配体的亲和力和选择性。该方法应用于LY-334370（5-HT 1F受体的选择性激动剂），以生成结构明确的二价分子。对三种克隆的5-HT 1受体亚型（5-HT 1B，5-HT 1D，5-HT 1F）进行的放射性配体结合测定表明，一系列同源二聚体的亲和力在探索三个结构变量（接头长度，附件位置，功能）。特别地，衍生自单体（3）的一系列C 3-至C 3连接的二聚体显示出对5-HT 1D的高结合亲和力（例如，对于二聚体8，K i约为0.3 nM），但不与5结合-HT 1F（K i> 0.01 mM），提供> 10000倍的亚型选择性。

  DOI：

  10.1021/jm7011722

文献信息

• [EN] SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006012374A1

  公开（公告）日：2006-02-02

  The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

  本发明提供了一类化合物，包括其药用可接受的衍生物，用于治疗血管生成和相关疾病，如癌症。其中R为从7-异喹啉基、2-甲基-3-氧代-2,3-二氢吲哚-6-基、[1,6]-萘啶-3-基、[1,7]-萘啶-2-基、1-氧代-2,3-二氢苯并呋喃-4-基、3-氧代-2,3-二氢苯并呋喃-5-基、二氢苯并二氧杂环基、6-喹唑啉基、2-氨基-6-喹唑啉基、4-甲氨基-6-喹唑啉基、2,4-二氨基-6-喹唑啉基、3-氧代-3,4-二氢-1,4-苯并噁嗪-6-基、2,2-二氟-1,3-苯并二氧杂环-5-基和2,2,3,3-四氟-2,3-二氢-1,4-苯并二氧杂环-6-基中选择的9-或10-成员杂环基，其中每个基可选择地被一个或多个来自卤素、卤代烷基、C1-6烷基、C2-8烯基、C2-8炔基、N-二甲氨基-C1-6-烷基、N-二甲氨基-C1-6-烷氧基、氨基、烷基-羰基氨基、吗啉磺酰基、氨基磺酰基、噁唑基、吡咯基、吗啉基、羧基、氰基和乙酰基的取代基取代；其中式I中的R1从未取代或取代的苯基、5-6成员杂芳基、9-10成员双环杂环基和11-14成员三环杂环基中选择，式II中的R1从特定的双环杂环基中选择。
• Substituted alkylamine derivatives and methods of use
  申请人：Amgen Inc.

  公开号：US20030225106A1

  公开（公告）日：2003-12-04

  Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的胺对预防治疗疾病有效，如血管生成介导的疾病。本发明包括新的化合物、类似物、前药和药用可接受的盐，药物组合物和预防治疗疾病和其他疾病或状况的方法，包括癌症等。本发明还涉及制造这类化合物的过程以及在此类过程中有用的中间体。
• Designing Selective, High Affinity Ligands of 5-HT_1D Receptor by Covalent Dimerization of 5-HT_1F Ligands Derived From 4-Fluoro-<i>N</i>-[3-(1-methyl-4-piperidinyl)-1<i>H</i>-indol-5-yl]benzamide
  作者：Seok-Ki Choi、David Green、Anne Ho、Uwe Klein、Daniel Marquess、Robert Taylor、S. Derek Turner

  DOI：10.1021/jm7011722

  日期：2008.6.1

  that covalent dimerization of 5-HT 1 ligands is an effective design strategy to modulate affinity and selectivity of 5-HT 1 ligands. This approach was applied to LY-334370, a selective agonist of 5-HT 1F receptor, to generate structurally well-defined divalent molecules. Radioligand binding assays to three cloned 5-HT 1 receptor subtypes (5-HT 1B, 5-HT 1D, 5-HT 1F) demonstrated that the affinity of a

  我们在这里证明5-HT 1配体的共价二聚是一种有效的设计策略，以调节5-HT 1配体的亲和力和选择性。该方法应用于LY-334370（5-HT 1F受体的选择性激动剂），以生成结构明确的二价分子。对三种克隆的5-HT 1受体亚型（5-HT 1B，5-HT 1D，5-HT 1F）进行的放射性配体结合测定表明，一系列同源二聚体的亲和力在探索三个结构变量（接头长度，附件位置，功能）。特别地，衍生自单体（3）的一系列C 3-至C 3连接的二聚体显示出对5-HT 1D的高结合亲和力（例如，对于二聚体8，K i约为0.3 nM），但不与5结合-HT 1F（K i> 0.01 mM），提供> 10000倍的亚型选择性。
• Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT₆ Receptor Ligands
  作者：Jörg Holenz、Ramon Mercè、José Luis Díaz、Xavier Guitart、Xavier Codony、Alberto Dordal、Gonzalo Romero、Antoni Torrens、Josep Mas、Blas Andaluz、Susana Hernández、Xavier Monroy、Elisabeth Sánchez、Enrique Hernández、Raquel Pérez、Roger Cubí、Olga Sanfeliu、Helmut Buschmann

  DOI：10.1021/jm049615n

  日期：2005.3.1

  high selectivities against a wide range (>50) of other CNS relevant receptors. First, structure-affinity relationships of these ligands are discussed. In terms of functionality, high-affinity antagonists, as well as agonists and even partial agonists, were prepared. Compounds 19c and 19g represent the highest-affinity 5-HT(6) agonists ever reported in the literature. These valuable tool compounds should

  基于药物化学指导的假设药效团模型，新系列的吲哚基磺酰胺已被设计和制备为选择性和高亲和性5-羟色胺5-HT（6）受体配体。此外，基于发现库的筛选方法，一系列苯并恶嗪哌啶基磺酰胺被鉴定为选择性5-HT（6）配体。本文中描述的许多化合物具有出色的亲和力，显示的pK（i）值大于8（某些甚至大于9），并且对宽范围（> 50）的其他CNS相关受体具有高选择性。首先，讨论了这些配体的结构亲和性关系。就功能而言，制备了高亲和力的拮抗剂，以及激动剂，甚至部分激动剂。化合物19c和19g代表文献中报道的最高亲和力5-HT（6）激动剂。这些有价值的工具化合物应允许详细研究5-HT（6）受体在相关的动物模型疾病中的作用，例如认知缺陷，抑郁，焦虑或肥胖。
• Substituted indole compounds having NOS inhibitory activity
  申请人：Maddaford Shawn

  公开号：US20060258721A1

  公开（公告）日：2006-11-16

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

  本发明涉及一种一氧化氮合酶（NOS）的抑制剂，特别是那些选择性地抑制神经型一氧化氮合酶（nNOS）而不是其他NOS同工酶的抑制剂。本发明的NOS抑制剂，单独或与其他药用活性剂结合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥术（CABG）、伴或不伴有先兆的偏头痛、伴有疼痛性过敏的偏头痛、中枢性中风后疼痛（CPSP）、神经痛、吗啡/阿片类药物引起的耐受性和过度疼痛等疾病。